Japan Multiomics Market (2026-2031)
The Japan Multiomics Market was valued at $130.9 Million in 2026 and projected to reach to $217.6 Million by 2031, representing a compound annual growth rate of 10.7%. Japan's multiomics market is positioned for sustained expansion driven by the country's commitment to precision medicine and advanced healthcare technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan Multiomics Market Trends and Insights
- Japan is leveraging advanced genomic and proteomic technologies to enhance precision medicine and personalized healthcare delivery.
- The country's strong healthcare infrastructure, coupled with significant investments in biotechnology research, positions Japan as a key player in the Asia Pacific multiomics landscape. Driving Japan's market expansion are increasing adoption of integrated omics platforms in clinical diagnostics and drug development, alongside growing government support for genomic research initiatives.
- Japan's aging population and rising prevalence of chronic diseases are accelerating demand for multiomics-based diagnostic solutions.
- By 2031, Japan is expected to solidify its position as a regional leader in multiomics innovation and application..
Key Market Statistics
- CAGR (2026-2031) 10.7% CAGR
- Market Size, 2026 ~USD 130.9 Million
- Forecast, 2031 ~USD 217.6 Million
- Country Japan
Japan Multiomics Market Overview
Market Valuation Growth :
Japan's multiomics market is valued at $130.9 million in 2026 and is projected to reach $217.6 million by 2031, representing a robust 10.7% CAGR over the forecast period.
Precision Medicine Advancement :
Japan is leveraging advanced genomic and proteomic technologies to enhance precision medicine initiatives, enabling more targeted and personalized healthcare delivery across major medical institutions.
Strong Healthcare Infrastructure :
Japan's well-established healthcare system and aging population create significant demand for multiomics-driven diagnostic and therapeutic solutions to address chronic diseases and improve patient outcomes.
Biotechnology Investment :
Significant government and private sector investments in biotechnology research and development are accelerating the adoption of multiomics platforms in Japanese pharmaceutical and diagnostic companies.
Japan Multiomics Market Dynamics
- The aging demographic profile and prevalence of chronic diseases create strong demand for integrated genomic, proteomic, and metabolomic solutions.
- Japan's robust pharmaceutical sector and research institutions are increasingly adopting multiomics approaches to accelerate drug discovery and personalized treatment strategies. Government initiatives supporting biotechnology innovation and healthcare digitalization will further propel market growth through 2031.
- Strategic partnerships between Japanese biotech firms and global multiomics leaders are expected to enhance technology transfer and market penetration.
- The integration of multiomics data with artificial intelligence and big data analytics will unlock new clinical applications, positioning Japan as a key hub for precision medicine in the Asia-Pacific region..
Market Ecosystem
MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. | Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina) |
 |
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. | Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Japan's multiomics market is valued at $130.9 million in 2026 and will reach $217.6 million by 2031, representing a 10.7% CAGR.
- Japan's advanced healthcare infrastructure and government-backed genomic research initiatives are primary growth catalysts for multiomics adoption.
- Japan's aging demographic and rising chronic disease burden are driving demand for precision diagnostic and therapeutic solutions powered by multiomics.
- Japan is positioned as a regional innovation hub in Asia Pacific, with increasing integration of multiomics into clinical workflows and drug development pipelines.
Multiomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 12.3% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 3.19 (2026) |
| Revenue Forecast (Billions) | ~USD 5.7 (2031) |
| Segments Covered | Offering, Type, Technology, Method, Workflow, Application, End User |
Japan Multiomics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Assay Kits & Reagents
- Consumables
- Instruments & Software
- Long-Read Sequencing
- Ms-Based Proteomics
- Nanopore Sequencing
- Ngs-Based Proteomics
- Other Consumables
- Other Proteomics Methods
- Other Sequencing Technologies
- Pcr-Based Proteomics
- Smrt Sequencing
By Technology
- Long-Read Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Other Technologies
- Proteomics
- Sequencing
- Smrt Sequencing
By Method
- Chromatin Accessibility Sequencing
- Chromatin Interaction Analysis
- Dna Methylation Sequencing
- Epigenomics
- Histone Modification Profiling
- Long-Range Sequencing
- Long-Read & Long-Range Sequencing
- Long-Read Sequencing
- Ms-Based Proteomics
- Ngs-Based Proteomics
- Other Epigenomics Methods
- Other Long-Read & Long-Range Sequencing Methods
- Other Methods
- Other Proteomics Methods
- Other Single-Cell Omics
- Other Spatial Omics
- Pcr-Based Proteomics
- Proteomics
- Sequencing-Based Epigenomics
- Single-Cell Epigenomics
- Single-Cell Genomics
- Single-Cell Omics
- Single-Cell Proteomics
- Single-Cell Transcriptomics
- Spatial Epigenomics
- Spatial Genomics
- Spatial Omics
- Spatial Proteomics
- Spatial Transcriptomics
By Workflow
- Data Visualization & Analysis
- Sample Preparation
- Sequencing & Analysis/ Sample Characterization
- Sequencing & Analysis/Sample Characterization
By Application
- Biomarker Discovery
- Cell Biology
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Neurology
- Oncology
- Other Applications
- Precision Medicine
- Translational Research
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Hospitals & Diagnostic/Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
Target Audience
- Pharmaceutical Companies : Japanese and international pharma firms need Japan-specific multiomics market data to guide R&D investments, precision medicine strategies, and drug development pipelines targeting Japanese patients.
- Diagnostic & Biotech Firms : Multiomics technology providers and diagnostic companies require detailed Japan market intelligence to identify growth opportunities, competitive positioning, and customer acquisition strategies.
- Healthcare Investors : Venture capital, private equity, and institutional investors need Japan market analysis to evaluate investment opportunities in multiomics startups and established biotech companies.
- Hospital & Clinical Networks : Japanese healthcare institutions and hospital systems need market insights to assess multiomics adoption trends, technology vendors, and implementation strategies for precision medicine programs.
- Government & Policy Makers : Japanese health ministry officials and policy makers require market data to inform biotechnology funding decisions, healthcare innovation initiatives, and precision medicine regulatory frameworks.
Reasons to Buy this Report
- Japan-Specific Market Sizing : Access precise valuation data for Japan's multiomics market with detailed 2026-2031 forecasts, enabling accurate budgeting and investment decisions tailored to the Japanese healthcare landscape.
- Competitive Landscape Intelligence : Understand Japan's unique competitive dynamics, including local biotech players, pharmaceutical companies, and research institutions driving multiomics adoption in the region.
- Regulatory & Reimbursement Insights : Gain critical knowledge of Japan's healthcare regulations, reimbursement policies, and approval pathways specific to multiomics diagnostics and therapeutics.
- Growth Driver Analysis : Identify Japan-specific growth catalysts including aging population trends, government biotech initiatives, and precision medicine adoption rates influencing market expansion.
- Strategic Market Entry Planning : Develop informed go-to-market strategies for Japan with localized insights on healthcare infrastructure, key opinion leaders, and partnership opportunities in the multiomics sector.
Frequently asked questions
What is the current size of Japan's multiomics market?
Japan's multiomics market is valued at $130.9 million in 2026 and is projected to grow to $217.6 million by 2031.
What is the expected growth rate for Japan's multiomics market?
Japan's multiomics market is expected to grow at a compound annual growth rate (CAGR) of 10.7% from 2026 to 2031.
What are the main drivers of growth in Japan's multiomics market?
Key drivers include Japan's advanced healthcare infrastructure, government support for genomic research, an aging population, rising chronic disease prevalence, and increasing adoption of precision medicine approaches.
How does Japan's multiomics market compare to the global market?
Japan's multiomics market is growing at 10.7% CAGR, slightly below the global CAGR of 12.3%, reflecting Japan's mature healthcare system and steady, sustainable market expansion.
What applications are driving multiomics adoption in Japan?
Primary applications in Japan include clinical diagnostics, personalized medicine, drug development, and biomarker discovery, supported by integration into hospital and research laboratory workflows.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Multiomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.
Key Stakeholders
- Multiomics product & service providers
- Multiomics bioinformatics/data analysis companies
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Hospitals and diagnostic clinics
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe multiomics market, by country
- Further breakdown of the Rest of Asia Pacific multiomics market, by country
Company Analysis
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Multiomics Market Report
Full forecast, segment splits, and company analysis for all Multiomics Market.
- Canada Multiomics Market
- US Multiomics Market
- Germany Multiomics Market
- UK Multiomics Market
- France Multiomics Market
- Italy Multiomics Market
- Spain Multiomics Market
- China Multiomics Market
- South Korea Multiomics Market
- India Multiomics Market
- Australia Multiomics Market
- Brazil Multiomics Market
- Saudi Arabia Multiomics Market
- UAE Multiomics Market
- Rest Of Europe Multiomics Market
- Rest Of Asia Pacific Multiomics Market
- Rest Of Latin America Multiomics Market
- Rest Of GCC Countries Multiomics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
